Tags

Type your tag names separated by a space and hit enter

Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
Pediatrics. 1990 Apr; 85(4 Pt 2):682-9.Ped

Abstract

In 1985, the first capsular polysaccharide (polyribosylribitol-phosphate [PRP]) vaccine for Haemophilus influenzae type b was licensed and recommended for routine use in children between 24 and 60 months of age. In the United States, approximately 75% to 90% of invasive disease due to H influenzae type b occurs in infants younger than 24 months, a population for whom H influenzae type b polysaccharide vaccine is inadequately immunogenic and protective. In an effort to enhance the immunogenicity of H influenzae type b polysaccharide vaccine for children in the most susceptible age groups, conjugate vaccines have been developed in which the capsular PRP of H influenzae type b has been bound to a variety of carrier proteins, thereby conferring the vaccines with thymic-dependent attributes. One such conjugate vaccine, in which the carrier protein is diphtheria toxoid (PRP-D), was licensed in 1987 and has been recommended since 1988 for routine use in children 18 months of age and older. A second conjugate vaccine, in which an oligosaccharide derivative of H influenzae type b capsular PRP is coupled to CRM, a nontoxic mutant diphtheria toxin (oligo-CRM), was licensed in 1988 and is a sanctioned alternative to PRP-D. Another investigational conjugate vaccine, in which the polysaccharide is linked to the outer membrane protein of Neisseria meningitidis group B (PRP-OMPC), has been demonstrated to be both safe and immunogenic when administered in a two-dose schedule to 2- to 6-month-old infants. However, anti-PRP antibody levels decline significantly during the ensuing 10 to 15 months; they rise significantly in response to booster doses of either PRP or PRP-OMPC administered 10 to 15 months after the initial priming doses of PRP-OMPC.(ABSTRACT TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

Dashefsky B
University of Pittsburgh School of Medicine, Children's Hospital of Pittsburgh, PA 15213.
Wald E
No affiliation info available
Guerra N
No affiliation info available
Byers C
No affiliation info available

MeSH

Antibodies, BacterialBacterial Outer Membrane ProteinsBacterial VaccinesDiphtheria ToxoidDiphtheria-Tetanus-Pertussis VaccineDrug CombinationsFemaleHaemophilus VaccinesHaemophilus influenzaeHumansInfantMaleMeasles VaccineMeasles-Mumps-Rubella VaccineMumps VaccineNeisseria meningitidisPertussis VaccinePoliovirus Vaccine, InactivatedPoliovirus Vaccine, OralPolysaccharides, BacterialRandomized Controlled Trials as TopicRubella VaccineTetanus ToxoidVaccines, Combined

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

2107519

Citation

Dashefsky, B, et al. "Safety, Tolerability, and Immunogenicity of Concurrent Administration of Haemophilus Influenzae Type B Conjugate Vaccine (meningococcal Protein Conjugate) With Either Measles-mumps-rubella Vaccine or Diphtheria-tetanus-pertussis and Oral Poliovirus Vaccines in 14- to 23-month-old Infants." Pediatrics, vol. 85, no. 4 Pt 2, 1990, pp. 682-9.
Dashefsky B, Wald E, Guerra N, et al. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants. Pediatrics. 1990;85(4 Pt 2):682-9.
Dashefsky, B., Wald, E., Guerra, N., & Byers, C. (1990). Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants. Pediatrics, 85(4 Pt 2), 682-9.
Dashefsky B, et al. Safety, Tolerability, and Immunogenicity of Concurrent Administration of Haemophilus Influenzae Type B Conjugate Vaccine (meningococcal Protein Conjugate) With Either Measles-mumps-rubella Vaccine or Diphtheria-tetanus-pertussis and Oral Poliovirus Vaccines in 14- to 23-month-old Infants. Pediatrics. 1990;85(4 Pt 2):682-9. PubMed PMID: 2107519.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants. AU - Dashefsky,B, AU - Wald,E, AU - Guerra,N, AU - Byers,C, PY - 1990/4/1/pubmed PY - 1990/4/1/medline PY - 1990/4/1/entrez SP - 682 EP - 9 JF - Pediatrics JO - Pediatrics VL - 85 IS - 4 Pt 2 N2 - In 1985, the first capsular polysaccharide (polyribosylribitol-phosphate [PRP]) vaccine for Haemophilus influenzae type b was licensed and recommended for routine use in children between 24 and 60 months of age. In the United States, approximately 75% to 90% of invasive disease due to H influenzae type b occurs in infants younger than 24 months, a population for whom H influenzae type b polysaccharide vaccine is inadequately immunogenic and protective. In an effort to enhance the immunogenicity of H influenzae type b polysaccharide vaccine for children in the most susceptible age groups, conjugate vaccines have been developed in which the capsular PRP of H influenzae type b has been bound to a variety of carrier proteins, thereby conferring the vaccines with thymic-dependent attributes. One such conjugate vaccine, in which the carrier protein is diphtheria toxoid (PRP-D), was licensed in 1987 and has been recommended since 1988 for routine use in children 18 months of age and older. A second conjugate vaccine, in which an oligosaccharide derivative of H influenzae type b capsular PRP is coupled to CRM, a nontoxic mutant diphtheria toxin (oligo-CRM), was licensed in 1988 and is a sanctioned alternative to PRP-D. Another investigational conjugate vaccine, in which the polysaccharide is linked to the outer membrane protein of Neisseria meningitidis group B (PRP-OMPC), has been demonstrated to be both safe and immunogenic when administered in a two-dose schedule to 2- to 6-month-old infants. However, anti-PRP antibody levels decline significantly during the ensuing 10 to 15 months; they rise significantly in response to booster doses of either PRP or PRP-OMPC administered 10 to 15 months after the initial priming doses of PRP-OMPC.(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0031-4005 UR - https://www.unboundmedicine.com/medline/citation/2107519/Safety_tolerability_and_immunogenicity_of_concurrent_administration_of_Haemophilus_influenzae_type_b_conjugate_vaccine__meningococcal_protein_conjugate__with_either_measles_mumps_rubella_vaccine_or_diphtheria_tetanus_pertussis_and_oral_poliovirus_vaccines_in_14__to_23_month_old_infants_ DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓8]

Related Citations

More